Table 1. Main demographic and clinical features compared with the index study

|  |  |  |
| --- | --- | --- |
|  | **Turkey n=50** | **Italy n=118** |
| **Demographic characteristics** |  |  |
| Female/Male (n) | 18/32 | 72/46 |
| Age, years (mean ± SD) | 36.68 (13.2) | NA |
| Age ≤ 50 years (n, %) | 44 (88) | 66 (56) |
| Age > 50 years (n, %) | 6 (12) | 52 (44) |
| Education ≤ 13 years (n, %) | 25 (50) | 31 (26) |
| **Clinical characteristics** |  |  |
| IVIG (n, %) | 43 (86) | 105 (89) |
| SCIG (n, %) | 7 (14) | 13 (11) |
| BMI ≤ 18.5 (n, %) | 6 (12) | 9 (7) |
| BMI 18.6- 24.9 (n, %) | 28 (56) | 67 (57) |
| BMI ≥ 25 (n, %) | 16 (32) | 42 (36) |
| Disease duration, months (median, min-max) | 52.5 (6-384) | NA |
| Number of infections within 3 months (median, min-max) | 1 (0-3) | NA |
| Number of infections within 12 months (median, min-max) | 3 (0-12) | NA |

*SD: standard deviation, IVIG: intravenous immunoglobulin, SCIG: subcutaneous immunoglobulin, BMI: body mass index, NA: not available*

Table 2. Correlations of the CVID QoL scores with the SF-36

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **CVID QoL Global** | **Emotional functioning** | **Relational functioning** | **Gastrointestinal and skin symptoms** |
| **SF-36** |  |  |  |  |
| Physical functioning | -,554\*\* | -,504\*\* | -,461\*\* | -,496\*\* |
| Role-physical | -,613\*\* | -,631\*\* | -,472\*\* | -,287\* |
| Bodily pain | -,564\*\* | -,582\*\* | -,550\*\* | -,267 |
| General health | -,533\*\* | -,541\*\* | -,456\*\* | -,257 |
| Vitality | -,535\*\* | -,551\*\* | -,394\*\* | -,465\*\* |
| Social functioning | -,730\*\* | -,713\*\* | -,666\*\* | -,340\* |
| Role-emotional | -,503\*\* | -,517\*\* | -,372\*\* | -,305\* |
| Mental health | -,606\*\* | -,607\*\* | -,498\*\* | -,400\*\* |
| Physical component summary (PCS) | -,781\*\* | -,789\*\* | -,655\*\* | -,404\*\* |
| Mental component summary (MCS) | -,778\*\* | -,782\*\* | -,639\*\* | -,477\*\* |
| **GA** |  |  |  |  |
| PhGA | ,351\* | ,300\* | ,365\*\* | ,047 |
| PtGA | ,782\*\* | ,758\*\* | ,744\*\* | ,337\* |

*QoL: Quality of life, SF-36: short form-36, GA: general assessment, PhGA: physician general assessment, PtGA: patient general assessment*

*\*\*. Correlation is significant at the 0.01 level (2-tailed).*

*\*. Correlation is significant at the 0.05 level (2-tailed).*

Table 3. Comparisons of the CVID QoL scores between the Turkish, Italy and Norway study groups

|  |  |  |  |
| --- | --- | --- | --- |
| Characteristics | Global CVID QoL scores | | |
| Scores, median (min-max)  Scores, mean (± SD) | Scores, mean (± SD) | Scores, mean (± SD) |
| Turkey n=50 | Italy n=118 | Norway n=83 |
| Total | 32 (1-89)  36.4 (20.7) | 29 (16.5) | 37.4 (15.3) |
| Female | 45 (11-89)  47.38 (21.4) | 31.3 (16.4) | 38.6 (15.6) |
| Male | 27 (1-66)  30.2 (17.8) | 25.7 (14.2) | 33.8 (14.4) |
| Age ≤ 50 years | 33 (1-89)  37.3 (20.8) | 26.5 (15.5) | 37.7 (17.9) |
| Age > 50 years | 24.5 (8-61)  29.8 (20.7) | 32.6 (15.7) | 37.1 (11.8) |
| Education ≤ 13 years | 43 (4-89)  43.1 (21.7) | 32.1 (17.5) | 37.6 (18.8) |
| Education > 13 years | 26 (1-68)  29.6 (17.6) | 28.3 (15.3) | 37.2 (12.1) |
| SCIG | 21 (4-27)  17.7 (8.4) | *NA* | 41.1 (15.7) |
| IVIG | 37 (1-89)  39.4 (20.6) | *NA* | 34.5 (13.5) |
| BMI ≤ 18.5 | 38.5 (21-79)  45 (22.8) | 41.1 (11.4) | 39.3 (3) |
| BMI 18.6-24.9 | 31 (1-89)  35.7 (21.1) | 28.2 (15.8) | 37 (16.2) |
| BMI ≥ 25 | 35 (4-68)  34.3 (19.7) | 28 (15.9) | 35.5 (15.2) |

CVID QoL scores are presented as median (min-max) and mean (SD) in Turkish study group, mean (SD) in Italian and Norwegian group*. Abbreviations; CVID: common variable immunodeficiency, SD: standard deviation, SCIG: subcutaneous immunoglobulin, IVIG: intravenous immunoglobulin, NA: not available*